EVT:XETRA-Evotec SE (EUR)

COMMON STOCK | Drug Manufacturers-Specialty & Generic | XETRA

Last Closing Price

EUR 41.55

Change

0.00 (0.00)%

Market Cap

EUR 6.84B

Volume

0.48M

Avg Analyst Target

EUR 39.67 (-4.53%)

Avg User Target

EUR
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Evotec SE provides drug discovery and development solutions to pharmaceutical and biotechnology companies, academic institutions, foundations, and not-for-profit organizations worldwide. The company's EVT Execute segment offers drug discovery services, such as target identification and validation, hit identification, sample management, chemistry, drug metabolism and pharmacokinetics, research informatics and in silico drug discovery, proteomics and metabolomics, bio-reagents, in vitro biology, in vivo pharmacology, biomarkers, and antibody discovery; INDiGO, a program for accelerating drug development; integrated chemistry, manufacturing, and control services; integrated drug discovery services; and integrated pre-clinical development services. Its EVT Innovate segment is involved in developing drug discovery projects, assets, and platforms. The company's portfolio of research and development programs include diabetes and diabetic complications, fibrosis, immunology, infectious and inflammatory diseases, kidney and liver diseases, oncological and rare diseases, pain, respiratory diseases, and women's health. Evotec SE has a strategic collaboration with the University Hospital Erlangen regarding molecular analyses of biospecimens from the German chronic kidney disease cohort study. The company was founded in 1993 and is headquartered in Hamburg, Germany. Address: Manfred Eigen Campus, Hamburg, Germany, 22419

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-10-16 )

Largest Industry Peers for Drug Manufacturers-Specialty & Generic

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
MRK:XETRA MERCK Kommanditgesellschaft au..

N/A

EUR83.63B 30.64 15.80
ZOE:XETRA Zoetis Inc

N/A

EUR82.69B 50.52 27.92
DMP:XETRA Dermapharm Holding SE

N/A

EUR4.55B 37.10 20.66
PSG:XETRA PharmaSGP Holding SE

N/A

EUR0.29B 36.07 25.77
HAEK:XETRA HAEMATO AG

N/A

EUR0.13B 18.54 14.53
93M:XETRA MPH Health Care AG

N/A

EUR0.11B 10.19 9.69
93M1:XETRA MPH Health Care AG

N/A

EUR0.10B 10.19 N/A
4BSB:XETRA 4basebio AG

N/A

EUR0.09B 0.17 2.64
SBX:XETRA SynBiotic SE

N/A

EUR0.07B N/A N/A
4XT:XETRA XPhyto Therapeutics Corp

N/A

EUR0.06B N/A N/A

ETFs Containing EVT

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Drug Manufacturers-Specialty & Generic)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 37.22% 86% B 87% B+
Dividend Return N/A N/A N/A N/A N/A
Total Return 37.22% 71% C- 86% B
Trailing 12 Months  
Capital Gain 80.26% 75% C 91% A-
Dividend Return N/A N/A N/A N/A N/A
Total Return 80.26% 75% C 91% A-
Trailing 5 Years  
Capital Gain 738.38% 100% A+ 99% A+
Dividend Return N/A N/A N/A N/A N/A
Total Return 738.38% 100% A+ 99% A+
Average Annual (5 Year Horizon)  
Capital Gain 39.70% 100% A+ 95% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 39.70% 100% A+ 95% A
Risk Return Profile  
Volatility (Standard Deviation) 43.35% 25% F 14% F
Risk Adjusted Return 91.58% 75% C 92% A-
Market Capitalization 6.84B 78% C+ 84% B
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Drug Manufacturers-Specialty & Generic)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 59.96 14% F 17% F
Price/Book Ratio 7.71 56% F 16% F
Price / Cash Flow Ratio 152.94 13% F 1% F
EV/EBITDA 48.77 17% F 7% F
Management Effectiveness  
Return on Equity 16.82% 67% D+ 66% D
Return on Invested Capital 3.43% 50% F 44% F
Return on Assets 1.83% 33% F 39% F
Debt to Equity Ratio 45.79% 83% B 54% F
Technical Ratios  
Short Ratio N/A N/A N/A N/A N/A
Short Percent N/A N/A N/A N/A N/A
Beta 0.87 57% F 74% C
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (EUR)

Quarterly Financials (EUR)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Low debt

The company is less leveraged than its peers ,, and is among the top quartile, which makes it more flexible. However, do check the news and look at its sector. Sometimes this is low because the company is not growing and has no growth potential.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

What to not like:
High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Poor capital utilization

The company management has delivered below median return on invested capital in the most recent 4 quarters compared to its peers.

Poor return on assets

The company management has delivered below median return on assets in the most recent 4 quarters compared to its peers.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector